QUEBEC CITY, March 4, 2019 /CNW Telbec/ - Opsens Inc.
("Opsens") (TSX: OPS) (OTCQX: OPSSF) is pleased to announce the appointment of Mr. Alan
Milinazzo as Executive Chairman of the Board of Directors.
"We are delighted to see Alan, a renowned leader in the medical device industry, join us. Alan has had extensive success in
building high-performance commercial teams in interventional cardiology. Alan's extensive experience as executive of leading
global businesses and his expertise in driving adoption of new technologies for interventional cardiology, spine, and surgical
products will be a precious asset for Opsens," said Denis M. Sirois who is transitioning his
Chairmanship role to Mr. Milinazzo. Sirois continues, "Opsens will greatly benefit from Alan's broad board experience and
his outstanding track record of two decades of executive management in the healthcare industry".
"We have ambitious goals and our growth is just beginning. We are fortunate to have Alan join our board and benefit from his
deep knowledge of the North American and international interventional cardiology market, as we expand global marketing of our
optical-based FFR and dPR products to assess intracoronary pressure and designed to provide the lowest drift in the industry,"
said Louis Laflamme, President and CEO of Opsens.
"I am excited to be joining the Opsens board of directors at such a dynamic phase of the company's growth and evolution. The
company is well positioned to drive adoption of its state-of-the-art physiology and optical based technologies and to continue to
bring important innovation to the minimally invasive markets," said Mr. Milinazzo. "I am looking forward to working with the
Board and Management to accelerate and optimize the market opportunities for our technologies and in doing so, to unlock
significant value for our shareholders," he added.
Alan Milinazzo is a Partner at Heidrick & Struggles' in Boston and a member of the Global Healthcare and Life Sciences Practice specializing in the Medical Device
sector. Prior to joining Heidrick & Struggles, Alan was chief executive officer of InspireMD, a pioneer in embolic prevention
systems (EPS) for coronary and vascular applications. He previously served as President and Chief Executive Officer of Orthofix
International N.V., a $600 million publicly traded global orthopedic and Spine Company, as well as
general manager of Medtronic, Inc.'s coronary and peripheral vascular businesses where he was instrumental in the development and
commercialization of several key products, including the company's first coronary drug-coated stent platform, Endeavor. Mr.
Milinazzo also spent 12 years with Boston Scientific in multiple global sales and marketing leadership roles during a period of
unprecedented top line growth in the cardiology franchise.
Alan currently serves as a director of Flexion Therapeutics (Nasdaq: FLXN), CasMed (Nasdaq: CASM) and the Musculoskeletal
Transplant Foundation. Prior directorships included LDR Spine (Nasdaq LDRH acquired by Zimmer-Biomet) Medpace (acquired by PE
sponsor Cinven), HET Systems (acquired by Covidien) and LumenR (acquired by Boston Scientific). He earned a bachelor's
degree, cum laude, from Boston College and interned at the White House, the US House of
Representatives and the John F. Kennedy Library.
Denis M. Sirois remains on the BOD
"Opsens warmly thanks Denis M. Sirois for his contribution as he held the helm of the board for
the past four years. We are grateful for his innovative ideas and strategic thinking that have allowed Opsens to make great
strides," added Louis Laflamme. "Denis will remain on the Board to continue building the
Company," Laflamme concluded.
About Opsens Inc. (www.opsens.com or www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR and dPR in interventional cardiology. Opsens offers an advanced optical-based
pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product,
the OptoWire, is a 2nd-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and
excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 50,000 patients in more than 30
countries. It is approved for sale in the United States, European Union, Japan, and Canada.
Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing
solutions for critical applications.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance and achievements of Opsens to be materially different from any future results,
performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE OPSENS Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2019/04/c8896.html